Management of Morphine Toxicity
For suspected morphine toxicity, immediately stop the opioid, provide respiratory support with stimulation and oxygen, and administer titrated low-dose intravenous naloxone (20-100 μg every 1-2 minutes) only if severe respiratory depression is present (respiratory rate <8/min), while carefully monitoring to avoid precipitating withdrawal or pulmonary edema 1, 2.
Initial Assessment and Recognition
Morphine overdose presents with a characteristic triad:
- Progressive drowsiness and sedation
- Respiratory depression (decreased rate <8/min and increased expiratory pause)
- Risk of apnea 1
The key is distinguishing true opioid toxicity from natural disease progression, particularly in patients with advanced illness. Look specifically for the temporal relationship between dose escalation and symptom onset, and the presence of pinpoint pupils 2.
Immediate Management Algorithm
Step 1: Discontinue Morphine
Stop all opioid administration immediately 1.
Step 2: Airway and Breathing Support
- Stimulate the patient (physical stimulation may restore breathing)
- Provide supplemental oxygen
- Support ventilation if needed with bag-mask ventilation
- This takes priority over naloxone administration 3, 4, 2
Step 3: Naloxone Administration (When Indicated)
Only administer naloxone for severe respiratory depression (respiratory rate <8/min). The goal is to reverse respiratory depression while preserving analgesia 1.
Dosing protocol:
- Prepare 0.4 mg (1 mL) diluted to 10 mL with saline
- Administer 1 mL (40 μg) IV every 2 minutes
- Titrate until respiratory rate increases to ≥10/min
- Do NOT aim to fully reverse sedation or restore full consciousness 1
For maintenance after initial response:
- Infuse 2 ampoules (0.8 mg) diluted in 250 mL over 3-4 hours
- Repeat as necessary based on respiratory rate 1
Critical Pitfalls with Naloxone
Avoid excessive naloxone dosing, which can cause:
- Acute opioid withdrawal syndrome
- Sudden-onset pulmonary edema (responds to positive pressure ventilation)
- Return of severe pain 3
In patients on chronic opioids for pain management, life-threatening respiratory depression is actually rare, and aggressive naloxone use may cause more harm than benefit 2.
Post-Resuscitation Management
All patients must be observed in a healthcare setting until risk of recurrent toxicity is low 3, 4. This is non-negotiable.
Observation Duration:
- Morphine, fentanyl, or heroin overdose: Abbreviated observation may be adequate
- Long-acting or sustained-release opioids: Prolonged observation required (minimum 24 hours) 3, 4
Monitor for Recurrence:
Since naloxone's duration of action (2-4 hours) is shorter than morphine's effects, patients may develop recurrent CNS and respiratory depression. If this occurs, administer repeated small doses or continuous naloxone infusion 3, 4.
Special Populations Requiring Dose Adjustment
Renal Impairment
Morphine-6-glucuronide (M6G), an active metabolite, accumulates in renal failure and can cause severe, prolonged toxicity even with standard doses 5, 6, 7. These patients require:
- Much lower initial doses
- Longer intervals between doses
- Extended monitoring periods (toxicity may persist 48+ hours)
- Consider switching to fentanyl or buprenorphine (safer in renal failure) 8
Hepatic Impairment
Morphine clearance decreases with cirrhosis, increasing half-life 6. Use lower doses and cautious titration.
Elderly Patients
More susceptible to respiratory depression and arrest. Start at the low end of dosing ranges 6.
Management Without Naloxone
If the patient has opioid toxicity but no pain, simply reducing or stopping the opioid dose is often sufficient 2. Naloxone is not always necessary.
If the patient has both toxicity and ongoing pain, consider opioid rotation (switching to a different opioid at reduced equianalgesic doses) rather than naloxone 9, 10.
Transfer Criteria
Transfer to intensive care if:
- Persistent respiratory depression despite naloxone
- Hemodynamic instability
- Altered mental status not improving with treatment
- Home-based patients with severe toxicity 1
Seek specialist palliative care input for patients on chronic opioids 2.